Compare Stocks → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNASDAQ:GMTXNYSE:IBIONASDAQ:SEELNASDAQ:TRVN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsGMTXGemini Therapeutics$27.30+1.1%$52.98$1.16▼$14.10$1.18B-0.12189,291 shs366,451 shsIBIOiBio$1.89-0.5%$0.00$1.02▼$24.40$6.58M-3.513.08 million shs99,127 shsSEELSeelos Therapeutics$0.30-9.1%$0.73$0.29▼$49.80$4.12M1.88430,273 shs610,410 shsTRVNTrevena$0.38-2.6%$0.49$0.30▼$3.28$6.98M1.1181,730 shs61,305 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-87.23%GMTXGemini Therapeutics0.00%-10.83%-54.62%-57.35%-9.55%IBIOiBio-1.05%+0.53%+50.00%+188,999,900.00%+188,999,900.00%SEELSeelos Therapeutics-7.98%-9.34%-39.06%-71.33%-98.50%TRVNTrevena-1.80%-4.32%-12.41%-40.86%-39.04%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos Therapeutics1.8957 of 5 stars3.24.00.00.00.60.00.0TRVNTrevena1.7505 of 5 stars3.53.00.00.02.50.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/ASEELSeelos Therapeutics2.33Hold$70.0023,155.81% UpsideTRVNTrevena3.00Buy$9.002,262.20% UpsideCurrent Analyst RatingsLatest TRVN, GMTX, SEEL, ADMP, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AIBIOiBio$2.38M2.76N/AN/A$15.15 per share0.12SEELSeelos Therapeutics$2.20M1.87N/AN/A($3.42) per share-0.09TRVNTrevena$3.13M2.23N/AN/A($0.44) per share-0.87Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AIBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/ASEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)TRVNTrevena-$40.29M-$3.13N/AN/AN/AN/A-1,018.15%-98.93%5/20/2024 (Estimated)Latest TRVN, GMTX, SEEL, ADMP, and IBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19GMTXGemini TherapeuticsN/A71.4971.49IBIOiBio0.040.910.91SEELSeelos TherapeuticsN/A0.140.14TRVNTrevena8.354.664.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%GMTXGemini Therapeutics75.42%IBIOiBio7.90%SEELSeelos Therapeutics23.37%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%GMTXGemini Therapeutics12.90%IBIOiBio1.12%SEELSeelos Therapeutics5.40%TRVNTrevena2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableGMTXGemini Therapeutics3143.33 million37.74 millionNot OptionableIBIOiBio263.48 million3.45 millionN/ASEELSeelos Therapeutics1513.68 million12.94 millionOptionableTRVNTrevena2318.32 million17.88 millionOptionableTRVN, GMTX, SEEL, ADMP, and IBIO HeadlinesSourceHeadlineTrevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 22 at 2:16 AMTrevena Cross free art exhibition featuring local artistsmsn.com - April 21 at 8:56 PMTrevena gets grant for pharmaceutical composition for modulating S1P1 receptor activitypharmaceutical-technology.com - April 18 at 8:34 AMTrevena (TRVN) Price Target Decreased by 7.69% to 6.12msn.com - April 18 at 3:33 AMTrevena Inc TRVNmorningstar.com - April 5 at 11:56 PMDanny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In Bulgariamsn.com - April 4 at 2:44 AMTrevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital Environmentmsn.com - April 3 at 3:48 AMRecap: Trevena Q4 Earningsbenzinga.com - April 2 at 2:41 AMTrevena Reports Fourth Quarter 2023 Results and Provides Corporate Updateglobenewswire.com - April 1 at 7:00 AMTrevena gets grant for pharmaceutical process for preparing compound of formula (i)pharmaceutical-technology.com - March 28 at 10:37 AMTrevena files patent for treatment of acute respiratory distress syndrome using specific peptidespharmaceutical-technology.com - March 22 at 9:37 PMTrevena Cross cafe reopening as the Palm Tree Bistromsn.com - March 16 at 3:06 PMTrevena Cross Garden Centre, The Palm Tree Bistrofalmouthpacket.co.uk - March 14 at 1:26 PMThe Palm Tree Bistro at Trevena Cross Nurseries reopeningmsn.com - March 8 at 10:03 AMTrevena Stock (NASDAQ:TRVN), Short Interest Reportbenzinga.com - February 22 at 1:18 PMTrevena files to sell 2.78M shares for holdersmsn.com - January 10 at 7:29 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 8:45 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 3:44 PMTrevena announces private placement and warrant exercisemsn.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisemarkets.businessinsider.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 27 at 1:16 PMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’msn.com - December 16 at 1:50 AMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'msn.com - December 15 at 8:50 PMTrevena Awarded OLINVYK Agreement with Premier, Inc.finance.yahoo.com - December 4 at 8:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Gemini TherapeuticsNASDAQ:GMTXGemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.iBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.